Ensign Peak Advisors, Inc Neurocrine Biosciences Inc Transaction History

Ensign Peak Advisors, Inc

$56.1 Billion
Q3 2024

A detailed history of Ensign Peak Advisors, Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 174,835 shares of NBIX stock, worth $23.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

174,835

Previous 272,613 35.87%

Holding current value

$23.7 Million

Previous $37.5 Million 46.37%

% of portfolio

0.04%

Previous 0.07%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $11.2 Million - $15 Million	-97,778 Reduced 35.87%	174,835 $20.1 Million
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $15.4 Million - $16.9 Million	117,902 Added 76.21%	272,613 $37.5 Million
Q1 2024 May 14, 2024	BUY	$130.4 - $143.74 $10.7 Million - $11.8 Million	82,103 Added 113.08%	154,711 $21.3 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $1.34 Million - $1.67 Million	-12,613 Reduced 14.8%	72,608 $9.57 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $999,620 - $1.25 Million	-10,632 Reduced 11.09%	85,221 $9.59 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $2.46 Million - $2.88 Million	27,433 Added 40.1%	95,853 $9.04 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $1.52 Million - $1.98 Million	16,115 Added 30.81%	68,420 $6.93 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $839,459 - $999,453	7,866 Added 17.7%	52,305 $6.25 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $1.57 Million - $1.84 Million	-17,036 Reduced 27.71%	44,439 $4.72 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $342,191 - $451,816	-4,515 Reduced 6.84%	61,475 $5.99 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $424,701 - $555,776	-5,862 Reduced 8.16%	65,990 $6.19 Million
Q4 2021 Feb 11, 2022	SELL	$79.65 - $106.22 $2.8 Million - $3.73 Million	-35,105 Reduced 32.82%	71,852 $6.12 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $200,109 - $229,947	-2,322 Reduced 2.12%	106,957 $10.3 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $5.42 Million - $6.2 Million	60,600 Added 124.49%	109,279 $10.6 Million
Q1 2021 May 12, 2021	SELL	$87.57 - $119.4 $11 Million - $15 Million	-125,879 Reduced 72.11%	48,679 $4.74 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $2.91 Million - $3.63 Million	-33,501 Reduced 16.1%	174,558 $16.7 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $7.34 Million - $10.3 Million	76,370 Added 57.99%	208,059 $20 Million
Q2 2020 Aug 12, 2020	BUY	$85.09 - $130.36 $3.3 Million - $5.06 Million	38,789 Added 41.75%	131,689 $16.1 Million
Q1 2020 May 11, 2020	SELL	$75.11 - $113.76 $1.35 Million - $2.04 Million	-17,948 Reduced 16.19%	92,900 $8.04 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $9.62 Million - $13.1 Million	110,848 New	110,848 $11.9 Million

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Neurocrine Biosciences Inc Transaction History